ArticleJournal for immunotherapy of cancer2023

CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression.

Kristan Meetze et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.